Vaxcyte, Inc.
PCVX
$44.70
-$0.82-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.27% | -1.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.14% | 25.13% | |||
| Operating Income | -7.14% | -25.13% | |||
| Income Before Tax | -27.77% | -18.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -27.77% | -18.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -27.77% | -18.37% | |||
| EBIT | -7.14% | -25.13% | |||
| EBITDA | -7.15% | -25.59% | |||
| EPS Basic | -27.62% | -18.08% | |||
| Normalized Basic EPS | -27.62% | -18.07% | |||
| EPS Diluted | -27.62% | -18.08% | |||
| Normalized Diluted EPS | -27.62% | -18.07% | |||
| Average Basic Shares Outstanding | 0.12% | 0.25% | |||
| Average Diluted Shares Outstanding | 0.12% | 0.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||